Annals of Oncology Advance Access originally published online on October 14, 2005
Annals of Oncology 2006 17(1):131-134; doi:10.1093/annonc/mdj019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
1 Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran; 2 Pharmacology Department of Tehran University of Medical Sciences, Tehran; 3 Department of Haematology of Tarbiat Modaress University, Tehran, Iran
* Correspondence to: Dr K. Alimoghaddam, Haematology, Oncology and BMT Research Centre of Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave., Tehran 14114, Iran. Tel: +98-91-21711635; Fax: +98-21-88004140; E-mail: alimgh{at}ams.ac.ir
 |
Abstract |
|---|
 Top Abstract introductionmaterials and methodsresultsdiscussionReferences |
|---|
Introduction: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.
Materials and methods: We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT–PCR) on peripheral blood samples.
Results: Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1–57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically.
Conclusions: Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.
Key words: APL, arsenic trioxide, minimal residual disease
|
introduction |
|---|
|
TopAbstractintroductionmaterials and methodsresultsdiscussionReferences |
|---|
Acute promyelocytic leukemia (APL) is a well-defined subtype of leukemia with specific and peculiar characteristics. The most important characteristic of this disease is translocation between chromosomes 15 and 17 in leukemic cells and the presence of PML/RARA fusion gene product in affected cells [1
].
Today, accepted protocols for treatment of APL contain all-trans retinoic acid (ATRA), which is usually combined with an antracycline. Overall survival and 2–4 year event-free survival are 70–80% and 55–85%, respectively [2–10]. Maintenance therapy by ATRA with or without low-dose chemotherapy improves the results and reduces the relapse rate [6, 8, 11].
Recently, some groups observed that an ancient drug, arsenic trioxide, is useful for treatment of resistant or relapsed cases of APL after treatment with ATRA [12–15]. Arsenic trioxide is the most active single agent against APL cells, which induces maturation and apoptosis in APL cells [1] and reduces microvascular density of bone marrow.
Soignet et al. [16] showed that arsenic trioxide could induce a high molecular remission rate in relapsed APL cases. Today arsenic trioxide is accepted for treatment of such cases and has improved the results of treatment of APL, which is comparable to stem cell transplantation [17]. The role of this drug in the induction of remission or consolidation phase of new cases of APL is less clear.
The purpose of our study is to define the efficiency and the safety of arsenic trioxide in the treatment of new cases of APL and their follow-up.
|
materials and methods |
|---|
|
TopAbstractintroductionmaterials and methodsresultsdiscussionReferences |
|---|
Acute promyelocytic leukemia diagnosed by clinical manifestations, morphologic FAB criteria, cytogenetics or fluorescence in situ hybridization study for detection of t(15,17) and/or RT–PCR for PML-RARA transcript.
Between May 2000 and January 2005, 111 APL patients were enrolled in our study. Pregnant women and patients with severe renal, hepatic or cardiac dysfunction (creatinine >2 mg/dl, billirubin >5 mg/dl and ejection fraction <50%), and patients with intracranial hemmorhage at presentation, were excluded from this study.
Seventeen patients were relapsed and 94 were new cases. Three patients had relapsed after previous stem cell transplantation (one after allogeneic and two after autologous stem cell transplantation) and 14 patients had relapsed after previous treatment by ATRA and chemotherapy. None of the relapsed cases had used ATRA or chemotherapy for maintenance therapy.
Hematological values and clinical characteristics of patients are shown in Table 1. Arsenic trioxide was prepared as 10 mg/10 ml vials, manufactured by the pharmaceutical faculty of Tehran University of Medical Sciences and was approved by the Deputy of Food and Drugs of the Ministry of Health and Medical Education for this clinical trial.
|
This clinical trial was approved by a local ethics review board and consent forms were obtained before treatment.
induction of remission
After diagnosis of APL according to above criteria, arsenic trioxide was started immediately as a 2-h intravenous infusion of 0.15 mg/kg in 500 ml dextrose water. Treatment continued until achievement of complete remission by morphologic criteria or to a maximum of 60 days. Also, we did not use any chemotherapeutic agents or leukopheresis during treatment.
supportive care during treatment
Prothrombine time, activated partial thromboplastin time, fibrin degradation products, and fibrinogen were measured at the time of diagnosis and regularly during the treatment. In the presence of disseminated intravscular coagulopathy, fresh frozen plasma and platelets were transfused.
White blood cell counts and peripheral blood smears were observed daily. Liver and renal functions were assessed regularly and fasting blood sugar, sodium, potassium, calcium, magnesium and urine analysis were tested twice weekly. Electrocardiograms were studied every other day and QTc intervals measured. In case of prolonged QTc, magnesium and potassium were infused for correction of QTc. Patients' weight was measured daily and diuretics prescribed for severe edema or weight gain. If the liver enzymes increased to >10 times the upper limit of normal, or bilirubin to >5 mg/dl or creatinin to >2 mg/dl, arsenic trioxide was discontinued for several days. After correction of any abnormalities, drug administration was restarted with half of original dose and rapidly increased to full dose. In cases with hepatic or renal complications or APL differentiation syndrome during induction of remission phase, a full dose of arsenic trioxide was used as the consolidation phase, without any significant complications.
APL differentiation syndrome (defined as weight gain, fever, polyserositis and dyspnea with or without radiographic markers of pulmonary infiltration) was treated by dexamethasone 10 mg twice daily, until patients' symptoms improved. For patients whose APL differentiation syndrome progressed to adult respiratory distress syndrome or pulmonary hemorrhage, we immediately used assisted ventilation with oxygen supplement and activated factor seven (Novo seven®) for some patients.
Peripheral blood smears were observed daily and bone marrow studied every 10 days for remission and maturation evaluation.
After complete remission was achieved, treatment was discontinued and patients discharged.
consolidation therapy
After 28 days rest, consolidation therapy was started. It consisted of outpatient infusion of arsenic trioxide at daily dose of 0.15 mg/kg, 6 days a week, for a total of 28 infusions. During this period, patients visited every week and complete blood count (CBC), liver enzymes, renal function and electrocardiogram were evaluated.
follow-up
After consolidation therapy, patients visited every month and then every 3 months. At each visit, their CBC, liver and renal function were studied.
definition of outcome
Complete remission was defined using the classic definition: neutrophil count >1500/mm3, platelet count >100 000/mm3 and immature cells (promyelocytes and myeloblast) <5% of nucleated bone marrow cells. Disease-free survival was measured from the time of complete remission until relapse or censorship of patients' data. Overall survival was measured from the time of diagnosis and beginning of treatment by arsenic trioxide until the time of death or censorship of patients' data.
minimal residual disease
After complete remission, 48 patients evaluated for minimal residual disease (MRD). RT–PCR studies were performed on peripheral blood samples, searching for mRNA of PML-_RARA isoforms. MRD was studied after the consolidation phase and 12 months after complete remission. Sensitivity of RT–PCR was 10–3 for MRD detection. Sequences of forward and reverse primers are shown in Table 2.
|
statistical analysis
Median values were measured for complete remission and hospitalization time. Disease-free and overall survival were calculated using the Kaplan–Meier method. Importance of risk factors for relapse and survival (including age, sex, white blood cell count at presentation, APL differentiation syndrome, hyperleukocytosis, treatment as new case versus relapsed cases, and MRD status) calculated by Fisher's exact test, log-rank test and logistic regression.
|
results |
|---|
|
TopAbstractintroductionmaterials and methodsresultsdiscussionReferences |
|---|
complete remission
Complete remission was observed in 95 patients (85.6%). The median time for complete remission was 30 days (range 20–43). Median length of hospitalization was 32 days for the remission induction phase. Remission was observed in 82 new cases (86.3%) and 13 (76.5%) relapsed cases. This difference was not statistically significant. Sixteen patients died in the induction phase owing to complications of disease or treatment. Causes of death were cardiac arrest in two patients, APL differentiation syndrome in eight patients (with pulmonary hemorrhage and/or acute respiratory distress syndrome), cerebral hemorrhage in three patients and disseminated aspergilosis in one patient. Two patients did not respond and died due to disease progression after chemotherapy. The median time of death was day 20 (range 2–55) during the induction phase.
hyperleukocytosis
Median white blood cell count was 2050/mm3 at the time of diagnosis. In 18 patients (16.2%) white blood cell count was >10 000/mm3. Hyperleukocytosis (white blood cell count >10 000/mm3) occurred in 65 patients (58.6%) during treatment. The median day for the beginning of hyperleukocytosis was 10 days (range 2–22) after starting treatment and the median highest leukocyte count in this group was 49 500/mm3 (range 10 200–167 700). There was no significant difference in white blood cell count at disease onset between patients with and without hyperleukocytosis, and it did not increase early mortality of treatment. We did not observe any association between hyperleukocytosis and APL differentiation syndrome, remission rate and relapse rate. Overall and disease-free survival were not significantly different for patients with and without hyperleukocytosis.
APL differentiation syndrome
APL differentiation syndrome usually maifested as weight gain, fever and respiratory distress, and in fatal cases rapidly terminated in pulmonary hemorrhage and respiratory failure. This complication was observed in 23 patients (20.7%); 10 of them succumbed during this complication (eight died due to APL differentiation syndrome and respiratory failure, one due to brain and pulmonary aspergilosis after resolution of APL differentiation syndrome and one due to intracranial hemorrhage).
There was no difference between new cases and relapsed subgroups. The death rate was significantly higher in patients with APL differentiation syndrome (P < 0.006)
disease-free and overall survival analysis
Median time of follow-up was 16.5 months (range 1–57). Relapse was observed in 24 patients (25.3%) in complete remission and median time of relapse after first complete remission was 17 months. One- and 2-year disease-free survival for patients in complete remission was 88.3% and 63.7%, respectively.
Disease-free survival was the same in new cases and patients who were treated after relapse following previous ATRA and chemotherapy.
For patients who relapsed after the first course of arsenic trioxide treatment, treatment was restarted with arsenic trioxide with the same schedule as the first treatment. Nineteen complete remissions observed in this group (79.2%) and median time of relapse for this group was 18 months.
One- and 3-year survival for patients in complete remission were 94.5% and 87.6%, respectively (Figure 1). Survival was the same in new cases of acute promyelocytic leukaemia and patients who treated after relapse following previous ATRA and chemotherapy.
|
We could not find any independent risk factor for relapse and survival in complete remission patients, except positive MRD following consolidation or during follow-up (P = 0.01 and <0.0001 respectively).
molecular follow-up of patients
Forty-eight patients were followed up by semi-sensitive RT–PCR for detection of PML-RARA fusion gene mRNA during the first year after complete remission.
All patients were in complete hematological remission at the time of MRD assessment. RT–PCR was positive in four patients (8.3%), three of whom relapsed clinically.
retreatment of relapse
Twenty-four patients who relapsed were retreated with the same treatment (arsenic trioxide) as before. Again, we observed 19 complete remissions (79.2%), and five patients died during second remission induction by arsenic trioxide.
|
discussion |
|---|
|
TopAbstractintroductionmaterials and methodsresultsdiscussionReferences |
|---|
We suggest that the complete remission rate of new cases of APL treated by arsenic trioxide is comparable to an ATRA–chemotherapy regimen.
In European APL study group experience, event-free survival was 84% for patients who were treated by concomitant chemotherapy and ATRA and 77% for patients on a sequential regimen [18].
With arsenic trioxide alone, overall survival and complete remission rates were comparable to those of the European group study, although we suggest that adding maintenance therapy by intermittent infusion of arsenic trioxide with or without oral chemotherapy, or adding chemotherapy to induction or consolidation phase, may improve results. Recently, we increased the consolidation phase of arsenic trioxide to four cycles (two cycles after complete remission, and one 1 year and 2 years after complete remission, to reduce relapse rate).
ATRA without chemotherapy could not induce a durable remission [19–22], so we suggest that arsenic trioxide is superior to ATRA for new cases and can induce a durable remission and good disease-free survival. Also, long-term treatment with ATRA can induce drug metabolism in the liver, which reduces its efficiency. So possibly, arsenic trioxide would be part of frontline regimen in future.
In APL patients treated with arsenic trioxide, the most important limitation was APL differentiation syndrome, which is sometimes fatal. Although it is possible to control this complication by corticosteroids, better supportive care and use of activated factor seven in patients with pulmonary hemorrhage, it is sometimes fatal. This should be a subject for future studies to control this complication by early chemotherapy, use of ATRA in combination with arsenic trioxide and improved supportive care.
Detection of MRD is another possible subject for study to improve the results of treatment and to start arsenic trioxide early for these patients. It has been shown that if MRD is negative twice after complete remission, risk of relapse is minimal [5, 23, 24]. By a more sensitive RT–PCR (10–4 versus 10–3 in our study) after induction phase, Soignet et al. [16] observed that 85% of patients were negative for MRD. In our study, MRD was negative in 91.7% of patients for 1 year after complete remission.
Also, we suggest that early treatment after detection of MRD may improve the results of arsenic trioxide therapy and may prevent high mortality of relapse [25–27].
Recently, we completed a study on patients' samples by a sensitive quantitative real-time PCR every 3 months, and we could define a threshold for relapse (unpublished data), which will be useful for early detection and treatment to improve results. We suggest that quantitative PCR is more accurate and predictive than regular PCR, and should be repeated for each patients at regular intervals (at least every 3 months, during first 2–3 years after remission) to predict relapse and early treatment.
Received for publication July 10, 2005. Revision received August 5, 2005. Accepted for publication August 8, 2005.
|
References |
|---|
|
TopAbstractintroductionmaterials and methodsresultsdiscussionReferences |
|---|
1. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298–4302.
2. Fenaux P, Castaigne S, Dombret H et al. All transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176–2181.
3. Ohno R, Yoshida H, Fukutani H et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 1722–1728.[Medline]
4. Kanamaru A, Takemoto Y, Tanimoto M et al. Alltrans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202–1206.
5. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML-RAR positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014–1021.
6. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.
7. Fenaux P, Le Deley MC, Castaigne S et al. Alltrans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993; 82: 3241–3249.
8. Tallman MS, Andersen JW, Schiffer CA et al. Alltrans retinoid acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
9. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999; 93: 4131–4143.
10. Fenaux P, Chevret S, Guerci A et al. Long-term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000; 14: 1371–1377.[CrossRef][Web of Science][Medline]
11. Fenaux P, Chastang G, Chevret S et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.
12. Sun H, Ma L, Hu X, Zhang T. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992; 12: 170–172.
13. Zhang P, Wang S, Hu X. Arsenic trioxide treated cases of acute promyelocytic leukemia. Chin Hematol 1996; 17: 58–62.
14. Shen Z, Chen G, Ni J. Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.
15. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
16. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
17. Au WY, Lie AKW, Chim CS et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752–758.
18. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
19. Huang ME, Ye YC, Chen SR et al. Use of alltrans retinoic acid in the treatment of APL. Blood 1988; 72: 567–572.
20. Chen ZX, Xue YQ, Zhang R et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419.
21. Castaigne S, Chomienne C, Daniel MT et al. Alltrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709.
22. Castaigne S, Chomienne C, Daniel MT et al. Retinoic acids in the treatment of acute promyelocytic leukemia. Nouv Rev Fr Hematol 1990; 32: 36–38.
23. Grimwade D, Howe K, Langabeer S et al. Minimal residual disease detection in acute promyelocytic leukemia reverse transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61–66.[Medline]
24. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998; 92: 784–789.
25. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.
26. Hoffman R, Haddad N, Sahar D et al. High-dose cytarabine therapy induces a molecular remission in APL patients who failed to achieve a complete response following treatment with ATRA and anthracyclines. Blood 1998; 92: 2517 (Abstr).
27. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12–22.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Nowak, D. Stewart, and H. P. Koeffler Differentiation therapy of leukemia: 3 decades of development Blood, April 16, 2009; 113(16): 3655 - 3665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hu, Y.-F. Liu, C.-F. Wu, F. Xu, Z.-X. Shen, Y.-M. Zhu, J.-M. Li, W. Tang, W.-L. Zhao, W. Wu, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia PNAS, March 3, 2009; 106(9): 3342 - 3347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Y. Wang and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood, March 1, 2008; 111(5): 2505 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Tallman and J. K. Altman Curative Strategies in Acute Promyelocytic Leukemia Hematology, January 1, 2008; 2008(1): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity Haematologica, June 1, 2007; 92(6): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lo-Coco, E. Ammatuna, and M. A. Sanz Current treatment of acute promyelocytic leukemia Haematologica, March 1, 2007; 92(3): 289 - 291. [Full Text] [PDF]
|
|
|
|
|
|
X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, and M. Ruthardt Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells Haematologica, March 1, 2007; 92(3): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group J. Clin. Oncol., December 20, 2006; 24(36): 5703 - 5710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghaffari, S Rostami, D Bashash, K Alimoghaddam, and A Ghavamzadeh Real-time PCR analysis of PML-RAR{alpha} in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy Ann. Onc., October 1, 2006; 17(10): 1553 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Tallman From rags to riches Blood, May 1, 2006; 107(9): 3425 - 3425. [Full Text] [PDF]
|
|
|
|
|
|
D. Douer ATO: the forefront of APL treatment? Blood, April 1, 2006; 107(7): 2588 - 2589. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sanz Treatment of Acute Promyelocytic Leukemia Hematology, January 1, 2006; 2006(1): 147 - 155. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||